NCT04019470
Withdrawn
Not Applicable
Immunomodulation Analysis on Peripheral Blood Mononuclear Cells of Radiation Therapy in Pediatric Malignant Brain Tumors
Capital Medical University1 site in 1 countryFebruary 1, 2019
ConditionsBrain Tumor, Pediatric
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Brain Tumor, Pediatric
- Sponsor
- Capital Medical University
- Locations
- 1
- Primary Endpoint
- The changes of peripheral blood immune cells
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
To investigate the effect of radiotherapy on peripheral blood immune cell composition and function in pediatric malignant brain tumor patients.
Investigators
Jun Ren MD, PhD
Cancer Center Director
Capital Medical University
Eligibility Criteria
Inclusion Criteria
- •Age from 3 to 18
- •To be diagnosed with malignant brain tumors
- •To eligible for radiation therapy
- •Karnofsky performance status ≥ 70
- •No prior radiation exposure
- •Informed consent signed for blood sample collection and used for research purpose
Exclusion Criteria
- •Patients had received radiotherapy previously.
- •Patients who had no histological diagnosis
- •Patients who do not wish to participate
- •Patients with infections
Outcomes
Primary Outcomes
The changes of peripheral blood immune cells
Time Frame: 6 weeks (prior and post the radiation therapy )
The flow cytometric analysis of lymphocyte subtypes populations would be performed
Secondary Outcomes
- The changs of inflammatory cytokines and chemokines(6 weeks (prior and post the radiation therapy ))
- Activation status of T cells(6 weeks (prior and post the radiation therapy ))
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local MicrobiomeBreast CancerProstate CancerNCT03383107Weill Medical College of Cornell University66
Active, not recruiting
Not Applicable
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic responseEUCTR2012-001786-32-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI19
Active, not recruiting
Not Applicable
PRediction of Outcomes and PERsonalized Radiotherapy by Biomarkers and Functional ImagingRectal Cancer, RadiotherapyNCT06730035IRCCS Azienda Ospedaliero-Universitaria di Bologna30
Recruiting
Not Applicable
Investigating the Tumour Immune Response of RadiotherapyCancerNCT05076500University of Manchester120
Recruiting
Not Applicable
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric AdenocarcinomaHepatocellular CarcinomaBiliary Tract CarcinomaColorectal AdenocarcinomaNCT06349044Zhejiang Cancer Hospital120